Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST)

被引:387
作者
Wahlgren, Nils [1 ]
Ahmed, Niaz [1 ]
Eriksson, Niclas [2 ]
Aichner, Franz [3 ]
Bluhmki, Erich [4 ]
Davalos, Antoni [5 ]
Erila, Terttu [6 ]
Ford, Gary A. [7 ]
Grond, Martin [8 ]
Hacke, Werner [9 ]
Hennerici, Michael G. [10 ]
Kaste, Markku [11 ]
Koehrmann, Martin [12 ]
Larrue, Vincent [13 ]
Lees, Kennedy R. [14 ,15 ]
Machnig, Thomas [4 ]
Roine, Risto O. [16 ]
Toni, Danilo [17 ]
Vanhooren, Geert [18 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Neurol, Stockholm, Sweden
[2] Uppsala Univ, Uppsala Clin Res Ctr, Uppsala, Sweden
[3] Wagner Jauregg Linz, Dept Neurol, Linz, Austria
[4] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[5] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Dept Neurosci, Barcelona, Spain
[6] Tampere Univ Hosp, Dept Neurol, Tampere, Finland
[7] Newcastle Gen Hosp, Freeman Hosp Stroke Serv, Newcastle Upon Tyne, Tyne & Wear, England
[8] Kresklinikum Siegen, Siegen, Germany
[9] Univ Heidelberg, Dept Neurol, Heidelberg, Germany
[10] Univ Heidelberg, Dept Neurol, D-6800 Mannheim, Germany
[11] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland
[12] Neurol Univ Klin Erlangen, Stationsarzt Stroke Unit, Erlangen, Germany
[13] Hop Rangueil, Dept Neurol, Toulouse, France
[14] Univ Glasgow, Div Cardiovasc & Med Sci, Acute Stroke Unit, Glasgow, Lanark, Scotland
[15] Univ Glasgow, Div Cardiovasc & Med Sci, Cerebrovasc Clin, Glasgow, Lanark, Scotland
[16] Turku Univ Hosp, Dept Neurol, FIN-20520 Turku, Finland
[17] Univ Roma La Sapienza, Dept Neurol, Rome, Italy
[18] Dept Neurol, Brugge, Belgium
关键词
monitoring; multivariate; safety; stroke; thrombolysis;
D O I
10.1161/STROKEAHA.107.510768
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-The Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) unadjusted results demonstrated that intravenous alteplase is well tolerated and that the effects were comparable with those seen in randomized, controlled trials (RCTs) when used in routine clinical practice within 3 hours of ischemic stroke onset. We aimed to identify outcome predictors and adjust the outcomes of the SITS-MOST to the baseline characteristics of RCTs. Methods-The study population was SITS-MOST (n=6483) and pooled RCTs (n=464) patients treated with intravenous alteplase within 3 hours of stroke onset. Multivariable, backward stepwise regression analyses (until P <= 0.10) were performed to identify the outcome predictors for SITS-MOST. Variables appearing either in the final multivariable model or differing (P < 0.10) between SITS-MOST and RCTs were included in the prediction model for the adjustment of outcomes.Main outcome measures were symptomatic intracerebral hemorrhage, defined as National Institutes of Health Stroke Scale deterioration >= 1 within 7 days with any hemorrhage (RCT definition), mortality, and independency as defined by modified Rankin Score of 0 to 2 at 3 months. Results-The adjusted proportion of symptomatic intracerebral hemorrhage for SITS-MOST was 8.5% (95% CI, 7.9 to 9.0) versus 8.6% (6.3 to 11.6) for pooled RCTs; mortality was 15.5% (14.7 to 16.2) versus 17.3% (14.1 to 21.1); and independency was 50.4% (49.6 to 51.2) versus 50.1% (44.5 to 54.7), respectively. In the multivariable analysis, older age, high blood glucose, high National Institutes of Health Stroke Scale score, and current infarction on imaging scans were related to poor outcome in all parameters. Systolic blood pressure, atrial fibrillation, and weight were additional predictors of symptomatic intracerebral hemorrhage. Current smokers had a lower rate of symptomatic intracerebral hemorrhage. Disability before current stroke (modified Rankin Score 2 to 5), diastolic blood pressure, antiplatelet other than aspirin, congestive heart failure, patients treated in new centers, and male sex were related to high mortality at 3 months. Conclusions-The adjusted outcomes from SITS-MOST were almost identical to those in relevant RCTs and reinforce the conclusion drawn previously in the unadjusted analysis. We identified several important outcome predictors to better identify patients suitable for thrombolysis. (Stroke. 2008; 39: 3316-3322.)
引用
收藏
页码:3316 / 3322
页数:7
相关论文
共 20 条
[1]   Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke [J].
Brott, T ;
Broderick, J ;
Kothari, R ;
ODonoghue, M ;
Barsan, W ;
Tomsick, T ;
Spilker, J ;
Miller, R ;
Sauerbeck, L ;
Farrell, J ;
Kelly, J ;
Perkins, T ;
Miller, R ;
McDonald, T ;
Rorick, M ;
Hickey, C ;
Armitage, J ;
Perry, C ;
Thalinger, K ;
Rhude, R ;
Schill, J ;
Becker, PS ;
Heath, RS ;
Adams, D ;
Reed, R ;
Klei, M ;
Hughes, A ;
Anthony, J ;
Baudendistel, D ;
Zadicoff, C ;
Rymer, M ;
Bettinger, I ;
Laubinger, P ;
Schmerler, M ;
Meiros, G ;
Lyden, P ;
Dunford, J ;
Zivin, J ;
Rapp, K ;
Babcock, T ;
Daum, P ;
Persona, D ;
Brody, M ;
Jackson, C ;
Lewis, S ;
Liss, J ;
Mahdavi, Z ;
Rothrock, J ;
Tom, T ;
Zweifler, R .
STROKE, 1997, 28 (11) :2109-2118
[2]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[3]   The rtPA (Alteplase) 0-to 6-hour acute stroke trial, part A (A0276g) - Results of a double-blind, placebo-controlled, multicenter study [J].
Clark, WM ;
Albers, GW ;
Madden, KP ;
Hamilton, S .
STROKE, 2000, 31 (04) :811-816
[4]   Predicting outcome after acute and subacute stroke - Development and validation of new prognostic models [J].
Counsell, C ;
Dennis, M ;
McDowall, M ;
Warlow, C .
STROKE, 2002, 33 (04) :1041-1047
[5]   Systematic review of prognostic models in patients with acute stroke [J].
Counsell, C ;
Dennis, M .
CEREBROVASCULAR DISEASES, 2001, 12 (03) :159-170
[6]   Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].
Hacke, W ;
Kaste, M ;
Fieschi, C ;
von Kummer, R ;
Davalos, A ;
Meier, D ;
Larrue, V ;
Bluhmki, E ;
Davis, S ;
Donnan, G ;
Schneider, D ;
Diez-Tejedor, E ;
Trouillas, P .
LANCET, 1998, 352 (9136) :1245-1251
[7]  
HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017
[8]   THE MEANING AND USE OF THE AREA UNDER A RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE [J].
HANLEY, JA ;
MCNEIL, BJ .
RADIOLOGY, 1982, 143 (01) :29-36
[9]   Sex-based differences in the effect of intra-arterial treatment of stroke - Analysis of the PROACT-2 study [J].
Hill, Michael D. ;
Kent, David M. ;
Hinchey, Judith ;
Rowley, Howard ;
Buchan, Alastair M. ;
Wechsler, Lawrence R. ;
Higashida, Randall T. ;
Fischbein, Nancy J. ;
Dillon, William P. ;
Gent, Michael ;
Firszt, Carolyn M. ;
Schulz, Gregory A. ;
Furlan, Anthony J. .
STROKE, 2006, 37 (09) :2322-2325
[10]   Can multivariable risk-benefit profiling be used to select treatment-favorable patients for thrombolysis in stroke in the 3-to 6-hour time window? [J].
Kent, David M. ;
Selker, Harry P. ;
Ruthazer, Robin ;
Bluhmki, Erich ;
Hacke, Werner .
STROKE, 2006, 37 (12) :2963-2969